BellBrook Labs Awarded Patent on Transcreener® HTS Assay for Glycosyltransferases
Complete the form below to unlock access to ALL audio articles.
It was announced today that the U.S. Patent and Trademark Office has awarded BellBrook Labs' Transcreener® technology its fourth patent (U.S. 7,847,066) for their innovative Glycosyltransferase assay. There are over 200 glycosyltransferases encoded in the human genome that use either UDP-, GDP- or CMP-activated sugars as the donor substrates. UDP-glycosyltransferases are the most abundant and they play a key role in metabolism of drugs.
In the Transcreener® UDP Assay, the detection of UDP produced in the enzyme reaction allows for a universal system to measure UDP-glycosyltransferase activity with any acceptor substrate. Because it allows homogenous, mix-and-read detection, the Transcreener® HTS Assay platform offers significant advantages over other assay methods that require separation steps. In combination with existing Transcreener® assays for GDP and CMP, the newly patented technology will accelerate the discovery of improved drugs targeting glycosylation events in diseases, such as cancer, type II diabetes and neurodegeneration.
